April 26, 2018
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world’s leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios.
“We chose to work with InSysBio because of their rich experience in QSP modeling and fundamental knowledge in the field. Through this partnership, we hope to continue to improve drug development in asthma”, David Fairman, Senior Director Clinical Pharmacology Modelling and Simulation, GSK, Lourdes Cucurull-Sanchez, Manager Target Sciences, GSK.
“We are very pleased that GSK decided to continue work with us. It means InSysBio has shown itself as a partner with significant expertise and strength in QSP”, Oleg Demin Jr, Head of Business Development, InSysBio.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | August 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
1.
02 Aug 2021 16:17
InSysBio to take part in PharmSci360 2021
InSysBio announces its participation in AAPS 2021 PHARMSCI 360 which is to be held in Pennsylvania Convention Center, Philadelphia, PA, and Online 17-20 October, 2021. InSysBio team is going to present the update at the Virtual Booth (VB1) and 2 posters in frames of the Conference
|
3
|
4
|
5
|
6
1.
06 Aug 2021 15:38
InSysBio to participate in Biomarkers for Alzheimer’s Disease Summit
InSysBio will take part in Annual Biomarkers for Alzheimer’s Disease Summit, Digital Event which is going to be held August 24-26, 2021. InSysBio will present its Neurodegeneration modeling issues and Alzheimer’s Disease Platform update at its Virtual Booth! Moreover, Tatiana Karelina, Head of Neurodegenerative Diseases Modeling Team, will give a talk
|
7
|
8
|
|
9
|
10
|
11
1.
11 Aug 2021 15:50
InSysBio to launch its OpenSource HetaSimulator project
The new platform is a part of Heta-based QSP modeling infrastructure
[Moscow – 11.08.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, now presents HetaSimulator. It is a part of Heta project that embraces three components. HetaSimulator is an OpenSource simulation and parameters estimation platform for the Heta modeling language.
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
1.
18 Aug 2021 10:49
InSysBio to take part in PAGE 2021
InSysBio announces its participation in PAGE 2021 Online meeting which is to be held on the 2nd, 3rd, 6th, and 7th of September 2021. InSysBio team is going to present its latest development at the Virtual Exhibition e-booth and six posters
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
